Research programme: cardiovascular diagnostic imaging - Pharmacyclics

Drug Profile

Research programme: cardiovascular diagnostic imaging - Pharmacyclics

Latest Information Update: 28 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacyclics
  • Developer Johns Hopkins University School of Medicine; Pharmacyclics
  • Class Gadolinium-containing contrast agents; Texaphyrins
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery disease

Most Recent Events

  • 04 Jun 2004 Pharmacyclics is looking for a collaborative partner for the programme
  • 03 Jun 2004 Preclinical trials in Coronary artery disease (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top